Clinical Trial Update: Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating azacitidine in Chinese patients with higher-risk myelodysplastic syndrome has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndrome (MDS) | Phase 2 | Status: COMPLETED | Results posted: 2016-02-29